SCHEMBL4346859

SCHEMBL4346859

CC(O)c1cc(Cl)cc(NCc2ccccc2Sc2ccc(Cl)c(Cl)c2)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
GFER P55789 1/20 0.35
SLC6A4 P31645 7/20 0.34
SLC6A2 P23975 6/20 0.34
SLC6A3 Q01959 6/20 0.34
HTR1A P08908 1/20 0.34
HTR3A P46098 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ITGB2 P05107 1/20 0.33
ICAM1 P05362 1/20 0.33
ITGAL P20701 1/20 0.33
CYP3A4 P08684 3/20 0.32
KCNH2 Q12809 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353431 0.91 SLC6A4 (0.43) CYP2D6CYP2C9CYP2C19GFERSLC6A4
SCHEMBL4349621 0.89 SMN1; SMN2 (0.39) CYP2D6CYP2C9CYP2C19GFERSLC6A4
SCHEMBL4354059 0.89 SLC6A4 (0.47) CYP2D6CYP2C9CYP2C19GFERSLC6A4
SCHEMBL4346140 0.89 CYP2D6 (0.38) CYP2D6CYP2C9CYP2C19GFERSLC6A4
SCHEMBL4343716 0.87 ITGB2 (0.39) SLC6A4SLC6A2SLC6A3ITGB2ICAM1
SCHEMBL4345407 0.86 MEN1 (0.50) CYP2D6CYP2C9CYP2C19GFERSLC6A4
SCHEMBL4357669 0.86 GAA (0.40) GFERSLC6A4SLC6A2SLC6A3HTR1A
SCHEMBL4355882 0.84 MEN1 (0.39) CYP2D6CYP2C9CYP2C19GFERSLC6A4
SCHEMBL4357627 0.84 MAPT (0.41) CYP2D6CYP2C9CYP2C19GFERSMN1; SMN2
SCHEMBL4351061 0.84 LMNA (0.40) CYP2D6CYP2C9CYP2C19GFERSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 CYP2D6 191/4885CYP2C9 486/4885CYP2C19 976/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 CYP2D6 134/4885CYP2C9 464/4885CYP2C19 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.